Seqirus to spend $140M in N.C. flu vaccine plant expansion by Eric Sagonowsky Monday, November 19, 2018 Seqirus plans to add cell-based and adjuvanted flu vaccine capacity in a $140 million expansion to its plant in Holly Springs, North Carolina.
Officials deny shortage of Seqirus' Fluad in the U.K. by Eric Sagonowsky Wednesday, October 17, 2018 Seqirus says it is phasing delivery of its flu vaccine Fluad to the U.K. ahead of the peak season, though pharmacists have reported a lack of supply.
GSK, Seqirus begin shipping flu vaccines for the 2018-19 season by Angus Liu Tuesday, August 14, 2018 Seqirus expects to offer 50 million flu vaccine doses, while GSK plans to boost its supplies to 40 million to 45 million, its highest total ever.
Cell-based flu shots offer slight advantage for seniors: report by Angus Liu Wednesday, June 27, 2018 Seqirus' cell-based flu vaccine was 26.5% effective at keeping those 65 and older out of the hospital in the past flu season, an FDA study finds.
U.K. officials prep switch to Seqirus' Fluad in over-75s by Eric Sagonowsky Wednesday, January 3, 2018 Seqirus' adjuvanted flu vaccine Fluad is finally set for routine use in the U.K. because the current shot isn't working for the elderly.
Seqirus investing $52M to UK flu vax site and adding 100 jobs by Eric Palmer Thursday, November 9, 2017 Seqirus will invest £40 million into its U.K. site, adding about 100 jobs so it can shorten production time for its Fluad influenza vaccine.
Flu season early bird Seqirus debuts Fluad campaign by Beth Snyder Bulik Wednesday, August 23, 2017 Seqirus has debuted its first commercial for Fluad, in an early flu season campaign targeting the 65-plus crowd.
